Menu
05/08/2005
Breast cancer HRT risk lower than thought
A woman’s risk of developing breast cancer while taking hormone replacement therapy (HRT) might be lower than previously thought, according to new research.
In a study published in the British Medical Journal, researchers from the New South Wales Breast Cancer Institute estimated a woman’s individual risk of breast cancer up to the age of 79, in relation to HRT, using the latest data.
Researchers found that the cumulative absolute risk of breast cancer fell with increasing age in women who did not take HRT. The team said that the average baseline risk (from 40 – 79) is around 7.2% (1 in 14), which fell to 6.1% (1 in 16) at 50 years and 4.4% (1 in 23) at 60 years.
The team said that the use of HRT only resulted in a slight increase in a woman’s cumulative risk. The study found that the use of oestrogen only hormone replacement or short-term (around five years) use of combined therapy (using both progesterone and oestrogen); beginning at age 50 hardly affects the cumulative risk.
However, the use of combined therapy for around 10 years, was found to increase the cumulative risk to 7.7%, while researchers found that long-term use of oestrogen-only treatments had a “minimal effect” on breast cancer risk.
The study concluded that additional breast cancer risk is greater with combined therapy, especially if it was taken for over five years. However, once HRT is stopped, researchers say, a woman’s breast cancer risk returns to that of a non-user of the same age.
Commenting on the findings of the study, Professor John Boyages, Director of the New South Wales Breast Cancer Institute, said: “Although we found the additional breast cancer risk with hormone replacement therapy for an individual is very small, the effect on the general incidence of breast cancer would be greater, especially in populations with high levels of use.
“The reasons for taking hormone replacement therapy vary and decisions about its use must be made at an individual level. Our analysis provides women and clinicians with better information to make these choices.”
(KMcA/SP)
In a study published in the British Medical Journal, researchers from the New South Wales Breast Cancer Institute estimated a woman’s individual risk of breast cancer up to the age of 79, in relation to HRT, using the latest data.
Researchers found that the cumulative absolute risk of breast cancer fell with increasing age in women who did not take HRT. The team said that the average baseline risk (from 40 – 79) is around 7.2% (1 in 14), which fell to 6.1% (1 in 16) at 50 years and 4.4% (1 in 23) at 60 years.
The team said that the use of HRT only resulted in a slight increase in a woman’s cumulative risk. The study found that the use of oestrogen only hormone replacement or short-term (around five years) use of combined therapy (using both progesterone and oestrogen); beginning at age 50 hardly affects the cumulative risk.
However, the use of combined therapy for around 10 years, was found to increase the cumulative risk to 7.7%, while researchers found that long-term use of oestrogen-only treatments had a “minimal effect” on breast cancer risk.
The study concluded that additional breast cancer risk is greater with combined therapy, especially if it was taken for over five years. However, once HRT is stopped, researchers say, a woman’s breast cancer risk returns to that of a non-user of the same age.
Commenting on the findings of the study, Professor John Boyages, Director of the New South Wales Breast Cancer Institute, said: “Although we found the additional breast cancer risk with hormone replacement therapy for an individual is very small, the effect on the general incidence of breast cancer would be greater, especially in populations with high levels of use.
“The reasons for taking hormone replacement therapy vary and decisions about its use must be made at an individual level. Our analysis provides women and clinicians with better information to make these choices.”
(KMcA/SP)
Related UK National News Stories
Click here for the latest headlines.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
08 August 2003
HRT therapy can double breast cancer risk
Certain kinds of hormone replacement therapy (HRT) can double a woman's risk of breast cancer, according to major research study of more than a million women. Researchers found that post-menopausal women using combination HRT were twice as likely to develop breast cancer as non-users.
HRT therapy can double breast cancer risk
Certain kinds of hormone replacement therapy (HRT) can double a woman's risk of breast cancer, according to major research study of more than a million women. Researchers found that post-menopausal women using combination HRT were twice as likely to develop breast cancer as non-users.
11 August 2003
HRT users at greater risk of breast cancer, says research
Some kinds of hormone replacement therapy (HRT) have a much greater effect on a woman's risk of breast cancer than others, according to research published in the Lancet.
HRT users at greater risk of breast cancer, says research
Some kinds of hormone replacement therapy (HRT) have a much greater effect on a woman's risk of breast cancer than others, according to research published in the Lancet.
12 April 2006
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
18 July 2003
New research suggests fatty foods could double breast cancer risk
A new study has suggested that women who eat fatty foods could be doubling their risk of developing breast cancer. Researchers followed the 'food diaries' of more than 13,000 women from the Norfolk area, and found that a diet high in fat corresponded to an increased incident of breast cancer.
New research suggests fatty foods could double breast cancer risk
A new study has suggested that women who eat fatty foods could be doubling their risk of developing breast cancer. Researchers followed the 'food diaries' of more than 13,000 women from the Norfolk area, and found that a diet high in fat corresponded to an increased incident of breast cancer.
-
Northern Ireland WeatherToday:Gale, coastal severe gale, northwest winds ease from late afternoon. Scattered showers will fall as snow over the hills at first, becoming isolated from mid-afternoon. Maximum temperature 7 °C.Tonight:Showers, scattered in the evening, will clear by midnight leaving the night dry with clear spells. Cloud will spread east towards morning. Minimum temperature 2 °C.
